Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart

Claudia Heilmann; Ulrich Geisen; Friedhelm Beyersdorf; Lea Nakamura; Christoph Benk; Michael Berchtold-Herz; Georg Trummer; Christian Schlensak; Barbara Zieger

doi:10.1160/TH09-07-0497

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2010; 103(05): 962-967
DOI: 10.1160/TH09-07-0497

Theme Issue Article

Schattauer GmbH

Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart

Authors

Claudia Heilmann^*

¹Department of Cardiovascular Surgery, University Medical Center Freiburg, Freiburg, Germany
Ulrich Geisen^*

²Clinical Chemistry, University Medical Center Freiburg, Freiburg, Germany;
Friedhelm Beyersdorf

¹Department of Cardiovascular Surgery, University Medical Center Freiburg, Freiburg, Germany
Lea Nakamura

³Department of Pediatrics and Adolescent Medicine, University Medical Center Freiburg, Freiburg, Germany
Christoph Benk

¹Department of Cardiovascular Surgery, University Medical Center Freiburg, Freiburg, Germany
Michael Berchtold-Herz

¹Department of Cardiovascular Surgery, University Medical Center Freiburg, Freiburg, Germany
Georg Trummer

¹Department of Cardiovascular Surgery, University Medical Center Freiburg, Freiburg, Germany
Christian Schlensak

¹Department of Cardiovascular Surgery, University Medical Center Freiburg, Freiburg, Germany
Barbara Zieger

³Department of Pediatrics and Adolescent Medicine, University Medical Center Freiburg, Freiburg, Germany

Abstract

Summary

Unexplained bleeding episodes are associated with ventricular assist devices (VAD) and can occur in part due to acquired von Willebrand syndrome (AVWS). AVWS is characterised by loss of high molecular weight (HMW) multimers of von Willebrand factor (VWF) and decreased ratios of collagen binding capacity and ristocetin cofactor activity to VWF antigen. Loss of multimers can occur as VWF is subjected to increased shear stress, which occurs in presence of VADs. We studied 12 patients who required mechanical support of their native heart for terminal cardiac insufficiency. Nine patients underwent placement of a VAD, while three underwent placement of a total artificial heart (TAH), which is connected directly to heart and large cardiac vessels without cannulas. Within one day of VAD implantation, four of five patients evaluated demonstrated loss of HMW multimers and impaired VWF function. AVWS was present within two weeks of implantation in eight of nine patients, and in all seven tested patients after ≥3 months. Patients with different VAD types developed varying severities of AVWS. After VAD ex-plantation, HMW multimers were detectable and VWF function normalised in all patients. AVWS was not observed in the TAH patients studied. Our findings demonstrate that patients with an implanted VAD experience a rapid onset of AVWS that is quickly and completely reversed after device explantation. In addition, TAH patients do not develop AVWS. These results suggest that shear stress associated with exposure of blood to VAD cannulas and tubes may contribute to the development of AVWS.

Keywords

Acquired coagulation disorders - von Willebrand disease - surgery

Volltext

Referenzen

References
1 Geisen U, Heilmann C, Beyersdorf F. et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 2008; 33: 679-684.
2 Klovaite J, Gustafsson F, Mortensen SA. et al. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 2009; 53: 2162-2167.
3 Steinlechner B, Dworschak M, Birkenberg B. et al. Platelet dysfunction in out-patients with left ventricular assist devices. Ann Thorac Surg 2009; 87: 131-137.
4 Tiede A, Priesack J, Werwitzke S. et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 2008; 06: 569-576.
5 Velik-Salchner C, Eschertzhuber S, Streif W. et al. Acquired von Willebrand syndrome in cardiac patients. J Cardiothorac Vasc Anesth 2008; 22: 719-724.
6 Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol 2003; 10: 142-149.
7 Sadler JE, Budde U, Eikenboom JC. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Wille-brand Factor. J Thromb Haemost 2006; 04: 2103-2114.
8 Claus RA, Bockmeyer CL, Budde U. et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009; 101: 239-247.
9 Fujikawa K, Suzuki H, McMullen B. et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-1666.
10 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-4244.
11 Zhou Z, Han H, Cruz MA. et al. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 2009; 101: 1070-1077.
12 Bonnefoy A, Hoylaerts MF. Thrombospondin-1 in von Willebrand factor function. Curr Drug Targets 2008; 09: 822-832.
13 Xie L, Chesterman CN, Hogg PJ. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med 2001; 193: 1341-1349.
14 Baldauf C, Schneppenheim R, Stacklies W. et al. Shear-induced unfolding activates von Willebrand factor A2 domain for proteolysis. J Thromb Haemost 2009; 07: 2096-2105.
15 Zhang X, Halvorsen K, Zhang CZ. et al. Mechanoenzymatic cleavage of the ultra-large vascular protein von Willebrand factor. Science 2009; 324: 1330-1334.
16 Tsai HM. Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost 2003; 29: 479-488.
17 Schneppenheim R, Thomas KB, Krey S. et al. Identification of a candidate mis-sense mutation in a family with von Willebrand disease type IIC. Hum Genet 1995; 95: 681-686.
18 Federici AB, Rand JH, Bucciarelli P. et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84: 345-349.
19 Mohri H. Acquired von Willebrand syndrome: features and management. Am J Hematol 2006; 81: 616-623.
20 Martin J, Siegenthaler MP, Friesewinkel O. et al. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study. Eur J Cardiothorac Surg 2004; 25: 971-977.
21 Siegenthaler MP, Martin J, van de Loo A, Doenst T. et al. Implantation of the permanent Jarvik-2000 left ventricular assist device: a single-center experience. J Am Coll Cardiol 2002; 39: 1764-1772.
22 Vincentelli A, Susen S, Le Tourneau T. et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-349.
23 Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand’s disease the link?. Lancet 1992; 340: 35-37.
24 Konig CS, Clark C, Mokhtarzadeh-Dehghan MR. Investigation of unsteady flow in a model of a ventricular assist device by numerical modelling and comparison with experiment. Med Eng Phys 1999; 21: 53-64.
25 Legendre D, Antunes P, Bock E. et al. Computational fluid dynamics investigation of a centrifugal blood pump. Artif Organs 2008; 32: 342-348.
26 Markl M, Benk C, Klausmann D. et al. Three-dimensional magnetic resonance flow analysis in a ventricular assist device. J Thorac Cardiovasc Surg 2007; 134: 1471-1476.
27 Moosavi MH, Fatouraee N. Flow simulation of a diaphragm-type ventricular assist device with structural interactions. Conf Proc IEEE Eng Med Biol Soc 2007; 2007: 1027-1030.
28 Heilmann C, Geisen U, Benk C. et al. Haemolysis in patients with ventricular assist devices: major differences between systems. Eur J Cardiothorac Surg 2009; 36: 580-584.
29 Malehsa D, Meyer AL, Bara C. et al. Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate II ventricular assist device. Eur J Cardiothorac Surg 2009; 35: 1091-1093.
30 Hampton CR, Verrier ED. Systemic consequences of ventricular assist devices: alterations of coagulation, immune function, inflammation, and the neuroendocrine system. Artif Organs 2002; 26: 902-908.